Picking a PARPi – what can the biology tell us?

How many observers realised there’s more than one member of the PARP family?

There’s quite a bit to be learned in the DNA damage repair (DDR) and replication stress niche, especially when it’s new targets, new tumour types and even new companies to look at.

In our latest post on this space we switch horses from big Pharma and continue the story with some interesting findings from the biotech side of the R&D fence.

This is a key trend we’ll be following going into ASCO next month as we start to see the layers peeled off the onion and get a lot at what’s working, where it’s working and just as importantly, what’s not…

To learn more about our ongoing post AACR21 and pre ASCO meeting analysis along with a company expert interview to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by